I.V Papavrine for Labor Induction in Term PROM

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: Premature Rupture of Membranes

In brief

This prospective randomized controlled trial aims to evaluate whether intravenous administration of papaverine 12 hours after term PROM reduces the interval from membrane rupture to delivery and improves maternal and neonatal outcomes. Researchers will compare drug papaverine to a placebo

Key facts

Study ID

NCT07517796

Run by

Western Galilee Hospital-Nahariya

People needed

110

Starts

2025-10-22

Expected to finish

2027-10-22

Last updated by the study team

2026-04-08

Who can join

Age: 18 and older, up to 45. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• • Singleton pregnancy
• Term gestation (37-42 weeks)
• Term PROM prior to active labor
• Duration of PROM <12 hours at enrollment
• Bishop score <8
• Cephalic presentation
• Viable fetus with reassuring fetal heart rate

You may not qualify if…

• • Multiple gestation
• Previous cesarean delivery
• Major fetal anomalies
• Contraindication to vaginal delivery
• Meconium-stained amniotic fluid
• Suspected chorioamnionitis

Where it is running

• Galilee Medical Center — Nahariya, Israel, Israel (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.